Apellis Pharmaceuticals, Inc.
APLS
주식 순위
#3324
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical... Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
주가
$41.03
마지막 동기화: 2026-05-15
시가총액
$5.25B
변동 (1일)
0.00%
변동 (1년)
51.57%
국가
US
거래 Apellis Pharmaceuticals, Inc. (APLS)
카테고리
Healthcare
Apellis Pharmaceuticals, Inc. (APLS)의 주식 분할 이력
Apellis Pharmaceuticals, Inc. 주식 (심볼: APLS)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Oct 20, 2026에 발생했습니다.
Oct 20, 2026 이전에 매수한 APLS 주식 1주는 현재 0주의 APLS 주식에 해당합니다.
가장 최근의 분할은 Oct 20, 2026에 발생했습니다.
Oct 20, 2026 이전에 매수한 APLS 주식 1주는 현재 0주의 APLS 주식에 해당합니다.
주식 분할 목록
| 연도 | 주식 분할 | 배수 | 누적 배수 |
|---|---|---|---|
| 제공된 날짜에 대한 데이터가 충분하지 않습니다. | |||
유사 기업 또는 경쟁사의 주식 분할
| 회사 | 주식 분할 횟수 | 누적 배수 | 국가 |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
